Atinary Technologies Announces Strategic Collaboration with Snapdragon Chemistry,
a Cambrex company
This collaboration will integrate Atinary’s AI-driven and automated process optimization technology with Snapdragon’s state-of-the-art laboratories and process development capabilities to tackle complex challenges in drug development.
MENLO PARK, California and LAUSANNE, Switzerland — September 26, 2024 — Atinary Technologies, whose leading no-code AI platform, SDLabsTM, and Self-Driving LabsTM technology are transforming research and development (R&D) of new molecules and chemicals, is thrilled to announce a strategic collaboration with Snapdragon Chemistry, a Cambrex company. Snapdragon is a recognized leader in active pharmaceutical ingredient (API) process development, with specialization in continuous flow process development, lab automation and complex synthetic APIs.
Through this collaboration, Snapdragon integrated its proprietary LabOSTM software platform with Atinary’s SDLabsTM platform to build a fully-automated and AI-driven, medium-throughput Solid-Phase Oligonucleotide Synthesizer (SPOS) for the purpose of autonomous multi-objective process optimizations. By using Atinary’s AI platform, Snapdragon’s process optimization campaign has demonstrated significant improvements across the tested applications, with up to an 18% increase in product yield and a 22% reduction in cost compared to processes previously optimized by an experienced scientist.
“Atinary is committed to accelerating innovation and delivering cutting-edge solutions to our customers,” said Dr. Hermann Tribukait, Co-Founder and CEO of Atinary Technologies. “Our work with Snapdragon showcases the power of our AI and data-driven process to solve complex chemistry and molecular discovery challenges in the pharmaceutical and biotech industry, orders of magnitude faster than traditional methods.”
Snapdragon’s state-of-the-art laboratories and process development capabilities, along with their ability to design and build self-contained reactors, will be instrumental in this collaboration.
“We are excited about the opportunity to expand Snapdragon’s technological capability by integrating Atinary’s AI technology in our process R&D activities”, said Dr. Eric Fang, General Manager of Snapdragon Chemistry. “We believe that our combined expertise and shared vision for accelerated innovation will lead to significant advancements and added value for our customers, streamlining and expediting drug development pipelines and R&D portfolios.”
For more information about Atinary Technologies and Snapdragon Chemistry, please visit www.atinary.com and www.cambrex.com/snapdragon.
About Atinary Technologies
Atinary accelerates optimization and discovery of breakthrough molecules and materials for our clients in pharma, biotech, consumer packaged goods, chemicals, energy, and climate tech.The sweet spot applications of our no-code AI platform and self-driving labs technology are in formulation, catalysis, and synthesis. Atinary’s vision is to transform R&D for the good of society. We aspire to accelerate the transition to a healthier and sustainable future by developing AI solutions that revolutionize science and R&D. For more information, please visit us at https://atinary.com/ and on Linkedin Atinary Technologies.
About Snapdragon Chemistry
Snapdragon Chemistry, a Cambrex company, specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon’s 70+ employees come with strong ties to the local scientific community, including more than 30 PhD scientists on staff.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services. With over 40 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs. For more information, please contact press@cambrex.com.
In the news
- Startupticker: Atinary wins over Snapdragon Chemistry in Massachusetts
- ContractPharma: Atinary, Snapdragon Partner to Tackle Challenges in Drug Development
- ManufacturingChemist: Snapdragon and Atinary develop a fully automated solid-phase oligonucleotide synthesiser
- Greater Geneva Bern area: Atinary Technologies and Snapdragon Chemistry partner to optimize drug development with AI
- swiss made software: Bringing AI to the development of active pharmaceutical ingredients
- DCAT Value Chain Insights: Cambrex, Atinary Technologies in AI Pact for Process Optimization
- Biopôle, BioAlps, Outsourced Pharma, PharmaSource, Speciality Chemicals Magazine, VBData, Pharmaceutical Online
